Drug Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Drug Name Ramucirumab
Trade Name Cyramza
Synonyms LY3009806
Drug Descriptions

Cyramza (ramucirumab) is a monoclonal antibody, which binds and inhibits VEGFR2 (KDR) resulting in decreased angiogenesis (PMID: 24094768). Cyramza (ramucirumab) is FDA approved for use as a monotherapy or in combination with paclitaxel in patients with gastric or gastroesophageal junction adenocarcinoma who progressed on chemotherapy, in combination with erlotinib as first-line therapy in patients with non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletion mutations or L858R, in combination with decetaxel in patients with NSCLC who progressed on prior therapy, in combination with FOLFIRI in patients with colorectal cancer who progressed on prior therapy, and as monotherapy in patients with hepatocellular carcinoma who have received sorafenib (FDA.gov).

DrugClasses VEGFR2 Antibody 4
CAS Registry Number 947687-13-0
NCIT ID C70792

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Therapy Name Drugs Efficacy Evidence Clinical Trials
Abemaciclib + Ramucirumab Abemaciclib Ramucirumab 0 2
AgenT-797 + Balstilimab + Botensilimab + Paclitaxel + Ramucirumab AgenT-797 Balstilimab Botensilimab Paclitaxel Ramucirumab 0 1
ALT-803 + Atezolizumab + Ramucirumab ALT-803 Atezolizumab Ramucirumab 0 1
Atezolizumab + Ramucirumab Atezolizumab Ramucirumab 0 1
Avelumab + Paclitaxel + Ramucirumab Avelumab Paclitaxel Ramucirumab 0 1
Capecitabine + Ramucirumab Capecitabine Ramucirumab 0 1
Capmatinib + Osimertinib + Ramucirumab Capmatinib Osimertinib Ramucirumab 0 1
Carboplatin + Paclitaxel + Ramucirumab Carboplatin Paclitaxel Ramucirumab 0 2
Cetuximab + Irinotecan + Ramucirumab Cetuximab Irinotecan Ramucirumab 0 1
Crenolanib + Paclitaxel + Ramucirumab Crenolanib Paclitaxel Ramucirumab 0 1
Cyclophosphamide + Ramucirumab + Vinorelbine Cyclophosphamide Ramucirumab Vinorelbine 0 2
Dacarbazine + Ramucirumab Dacarbazine Ramucirumab 0 0
Derazantinib + Paclitaxel + Ramucirumab Derazantinib Paclitaxel Ramucirumab 0 1
Dexamethasone + Docetaxel + Gemcitabine + Pemetrexed Disodium + Ramucirumab Dexamethasone Docetaxel Gemcitabine Pemetrexed Disodium Ramucirumab 0 1
Docetaxel + Gemcitabine + Ramucirumab Docetaxel Gemcitabine Ramucirumab 0 2
Docetaxel + Nivolumab + Ramucirumab Docetaxel Nivolumab Ramucirumab 0 1
Docetaxel + Pembrolizumab + Ramucirumab Docetaxel Pembrolizumab Ramucirumab 0 1
Docetaxel + Ramucirumab Docetaxel Ramucirumab 0 4
Durvalumab + Ramucirumab Durvalumab Ramucirumab 0 1
Emibetuzumab + Ramucirumab Emibetuzumab Ramucirumab 0 1
Erlotinib + Ramucirumab Erlotinib Ramucirumab 0 1
Evorpacept + Paclitaxel + Ramucirumab + Trastuzumab Evorpacept Paclitaxel Ramucirumab Trastuzumab 0 1
Fluorouracil + Irinotecan + Leucovorin + Ramucirumab Fluorouracil Irinotecan Leucovorin Ramucirumab 0 1
Fluorouracil + Leucovorin + Oxaliplatin + Ramucirumab Fluorouracil Leucovorin Oxaliplatin Ramucirumab 0 0
Gefitinib + Ramucirumab Gefitinib Ramucirumab 0 1
IMU-131 + Paclitaxel + Ramucirumab IMU-131 Paclitaxel Ramucirumab 0 1
Irinotecan + Ramucirumab Irinotecan Ramucirumab 0 1
Liposomal irinotecan + Ramucirumab Liposomal irinotecan Ramucirumab 0 1
Lorlatinib + Ramucirumab Lorlatinib Ramucirumab 0 1
LY3127804 + Ramucirumab LY3127804 Ramucirumab 0 0
LY3300054 + Ramucirumab LY3300054 Ramucirumab 0 1
Merestinib + Ramucirumab Merestinib Ramucirumab 0 1
Nab-paclitaxel + Ramucirumab Nab-paclitaxel Ramucirumab 0 2
Nivolumab + Ramucirumab Nivolumab Ramucirumab 0 2
Nivolumab + Ramucirumab + Rucaparib Nivolumab Ramucirumab Rucaparib 0 1
Octreotide + Ramucirumab Octreotide Ramucirumab 0 1
Olaparib + Ramucirumab Olaparib Ramucirumab 0 1
Oraxol + Ramucirumab Oraxol Ramucirumab 0 1
Osimertinib + Ramucirumab Osimertinib Ramucirumab 0 3
Oxaliplatin + Ramucirumab + Tegafur-gimeracil-oteracil Potassium Oxaliplatin Ramucirumab Tegafur-gimeracil-oteracil Potassium 0 0
Paclitaxel + Pembrolizumab + Ramucirumab Paclitaxel Pembrolizumab Ramucirumab 0 1
Paclitaxel + PRS-343 + Ramucirumab PRS-343 Paclitaxel Ramucirumab 0 1
Paclitaxel + Ramucirumab Paclitaxel Ramucirumab 0 13
Paclitaxel + Ramucirumab + Trastuzumab Paclitaxel Ramucirumab Trastuzumab 0 1
Paclitaxel + Ramucirumab + Trastuzumab + Tucatinib Paclitaxel Ramucirumab Trastuzumab Tucatinib 0 1
Paclitaxel + Ramucirumab + TRK-950 Paclitaxel Ramucirumab TRK-950 0 2
Paclitaxel + Ramucirumab + Tucatinib Paclitaxel Ramucirumab Tucatinib 0 1
Paclitaxel + Ramucirumab + XOMA 052 Paclitaxel Ramucirumab XOMA 052 0 1
Pembrolizumab + Ramucirumab Pembrolizumab Ramucirumab 0 8
Pembrolizumab + Ramucirumab + SAR408701 Pembrolizumab Ramucirumab SAR408701 0 1
Ramucirumab Ramucirumab 0 15
Ramucirumab + Rucaparib Ramucirumab Rucaparib 0 1
Ramucirumab + SAR408701 Ramucirumab SAR408701 0 2
Ramucirumab + Trastuzumab Ramucirumab Trastuzumab 0 1
Ramucirumab + Trifluridine-tipiracil hydrochloride Ramucirumab Trifluridine-tipiracil hydrochloride 0 4


Additional content available in CKB BOOST